Individualized dosing with KYNMOBI® (apomorphine HCl)

5 strengths available to help find your patient's optimal dose

  • KYNMOBI is available in 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg dose strengths1
    • The maximum single dose of KYNMOBI is 30 mg
  • Patients can take KYNMOBI when needed for any type of OFF episode, up to 5 times per day with at least 2 hours between doses1
    • If a single dose of KYNMOBI is ineffective for a particular OFF episode, a second dose should not be taken for that OFF episode. The efficacy or safety of administering a second dose for a single OFF episode has not been studied
  • An antiemetic (eg, trimethobenzamide 300 mg) is recommended, beginning 3 days prior to the initial dose of KYNMOBI but generally no longer than 2 months after the initial dose, given the incidence of nausea and vomiting1
KYNMOBI is available in 5 dose strengths: 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg.
KYNMOBI is available in 5 dose strengths: 10 mg, 15 mg, 20 mg, 25 mg, and 30 mg.
Prescribe KYNMOBI up to 5 times per day for any type of OFF episode, and it can be administered at the same time as carbidopa/levodopa in patients experiencing delayed ON/no ON1,2

Watch a short video to see how KYNMOBI is administered

Find out how to
prescribe KYNMOBI

References: 1. Kynmobi. Prescribing information. Sunovion Pharmaceuticals Inc; August 2021. 2. Olanow CW, Factor SA, Espay AJ, et al; for the CTH-300 Study Investigators. Apomorphine sublingual film for off episodes in Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 2020;19[2]:135-144. 3. Data on file. Sunovion Pharmaceuticals Inc. 4. Hui JS, Fox SH, Neeson W, et al; for the CTH-300 Study Investigators. Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and "OFF" episodes. Parkinsonism Relat Disord. 2020;79:110-116. 5. Ellenbogen AL, Nicholas AP, Hauser RA, Bhargava P, Pappert E, Navia B. Apomorphine sublingual film for the treatment of “off” episodes in patients with Parkinson’s disease: impact of concomitant antiemetics and dopamine agonists on nausea and vomiting. Poster presented at: International Parkinson and Movement Disorder Society Virtual Congress 2020; September 12-16, 2020; Milwaukee, WI. 6. US National Library of Medicine. Study NCT02542696. Accessed July 26, 2021. https://clinicaltrials.gov/ct2/show/NCT02542696.

Top

Thank you for registering with KYNMOBI!

We look forward to telling you more about KYNMOBI, a new medication to treat OFF episodes associated with Parkinson's disease, as it becomes available.

You have been successfully unsubscribed.

Please allow 7-10 days to process your request.